(Registrant's telephone number, including area
code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[
] Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
] Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
[
] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name of
each exchange on which registered
Common
Stock, par value $0.001 per share
CDXC
The
Nasdaq Capital Market
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the
Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth
company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
As previously disclosed, on December 29, 2016, ChromaDex, Inc.
filed a complaint in the United States District Court for the
Central District of California, naming Elysium Health, Inc.
(together with Elysium Health, LLC, “Elysium”) as
defendant (the “Complaint”). On January 25, 2017,
Elysium filed an answer and counterclaims in response to the
Complaint (together with the Complaint, the “California
Action”). The court previously set a jury trial to begin on
October 22, 2019.
On August 18, 2019, the parties filed motions for partial summary
judgment as to certain claims and counterclaims. The parties filed
opposition briefs on August 28, 2019, and reply briefs on September4, 2019. On October 9, 2019, among other things, the Court ordered
supplemental briefing with respect to certain issues related to
summary judgment, set the motion hearing date for January 13, 2020,
and vacated the October 22, 2019 trial date.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
